Prognostic Factors for Survival in Transverse Colon Cancers
- PMID: 34302255
- DOI: 10.1007/s12029-021-00675-1
Prognostic Factors for Survival in Transverse Colon Cancers
Abstract
Background: Transverse colon cancer (TCC) is a rare condition that accounts for 10% of all colon cancers. TCC was accepted more likely right-sided colon cancers. We aimed to investigate whether TCC differs from other colon tumors by using clinical, pathological, and molecular prognostic factors known to be important in colon cancer and if it differs in its own anatomical structure.
Patients and methods: We evaluated local and locally advanced TCC patients between 2007 and 2020 years for demographics data, symptoms, treatment status, and histopathological and molecular features.
Results: Overall, 107 TCC patients were included in this study. According to the molecular data analysis of 44, 35, and 23 patients for MSI, RAS, and BRAF status, respectively, 7 (15.9%) were MSI-H, 13 (37.1%) were RAS mutant, and 11 (47.8%) had BRAF V600E mutation. The median follow-up time was 31.5 months. Median disease-free survival (DFS) was 5.19 months, and median OS was 88.3 months for the whole study population. The tumor stage was the most significant prognostic factor for DFS and OS. Although BRAF mutation was not a significant marker for DFS, it was an independent prognostic marker for OS (HR 3.90 95% CI 1.42-10.7). There were no statistically significant differences between proximal two-thirds and distal one-third tumor location.
Conclusion: TCC has molecular features and prognostic factors more likely RCC and no differences between proximal and distal sub-parts. BRAF V600E mutation status is an independent predictor of survival even in the early stages of TCC.
Keywords: BRAF V600E; Pathological stage; Prognosis; Survival; Transverse colon cancer.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Nawa T, Kato J, Kawamoto H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol. 2008;23(3):418–23. - DOI
-
- Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterology Res. 2018;11(4):264–73. - DOI
-
- https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact... (Accessed on 20 Apr 2021).
-
- Benedix F, Schmidt U, Mroczkowski P, Gastinger I, Lippert H, Kube R. Colon carcinoma—classification into right and left sided cancer or according to colonic sub-site?–Analysis of 29,568 patients. Eur J Surg Oncol. 2011;37(2):134–9. - DOI
-
- Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary tumor location on overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(Suppl 4S):3504. - DOI
MeSH terms
Substances
LinkOut - more resources
Research Materials